Advertisement
U.S. markets open in 9 hours 25 minutes
  • S&P Futures

    5,206.75
    -8.00 (-0.15%)
     
  • Dow Futures

    39,197.00
    -26.00 (-0.07%)
     
  • Nasdaq Futures

    18,175.00
    -56.50 (-0.31%)
     
  • Russell 2000 Futures

    2,046.60
    -3.20 (-0.16%)
     
  • Crude Oil

    82.52
    -0.20 (-0.24%)
     
  • Gold

    2,164.60
    +0.30 (+0.01%)
     
  • Silver

    25.32
    +0.05 (+0.20%)
     
  • EUR/USD

    1.0878
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2724
    -0.0005 (-0.04%)
     
  • USD/JPY

    149.8490
    +0.7510 (+0.50%)
     
  • Bitcoin USD

    65,884.33
    -1,995.81 (-2.94%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,684.19
    -56.25 (-0.14%)
     

Codexis, Merck Extend Supply Pact For Enzyme Used To Manufacture Sitagliptin

  • Codexis Inc (NASDAQ: CDXS) has amended and extended its agreement with Merck & Co Inc (NYSE: MRK) to license and supply a proprietary enzyme used to manufacture sitagliptin.

  • Sitagliptin is an active pharmaceutical ingredient (API) in Merck's two anti-diabetic medications, Januvia and Janumet.

  • Codexis and Merck leveraged Codexis' CodeEvolver enzyme engineering platform technology to design an enzyme to serve as a biocatalyst in the sitagliptin manufacturing process.

  • In 2012 Codexis and Merck entered into a supply agreement for the enzyme and in 2015 signed a multi-year extension, which was to expire in February 2022.

  • The subsequent extension and amendment are for the license and supply of the proprietary enzyme through December 31, 2026.

  • The extension can be renewed for an additional five years.

  • Price Action: CDXS stock closed at $27.07 on Thursday, while MRK stock is up 0.56% at $74.23 during the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement